This study is for children with high-risk neuroblastoma, a type of cancer. The study checks if adding a medicine called dinutuximab to regular cancer treatments helps. Dinutuximab is a special protein that helps the body's defense system attack cancer cells. Doctors will compare two treatment groups: one with regular treatments like surgery, chemotherapy, and a stem cell transplant (taking and replacing healthy cells) and another with these plus dinutuximab. Kids who respond well after five treatment cycles will move to the next treatment phase. Those with poor responses might get more intense treatments.

• The study involves multiple cycles with different drugs and several hospital visits.
• The treatment could have side effects and requires immune system checks.
• Participation includes periodic follow-ups for up to 10 years.

Children must be under 30 years old, have specific cancer characteristics, and meet certain health criteria to join. Pregnant teens and those with some health conditions can't participate. Those who join must agree to regular testing and follow-up visits.